¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ IGET Symposium 2020 / Á¦29Â÷ Á¤±âÇмú´ëȸ ¹× ÃÑȸ(1ÀÏÂ÷) (¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà) : 2020-07-24

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ IGET Symposium 2020 / Á¦29Â÷ Á¤±âÇмú´ëȸ ¹× ÃÑȸ(1ÀÏÂ÷) (¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà) : 2020-07-24
±³À°ÀÏÀÚ : 2020-07-24
±³À°Àå¼Ò : ¿ÀÇÁ¶óÀÎ & ¿Â¶óÀÎ µ¿½Ã °³ÃÖ ¿¬¼ö±³À° (¿ÀÇÁ¶óÀÎ: °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B)  
±³À°ÁÖÁ¦ : IGET Symposium 2020 / Á¦29Â÷ Á¤±âÇмú´ëȸ ¹× ÃÑȸ(1ÀÏÂ÷) (¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà)
ÁÖÃÖ±â°ü : ´ëÇÑ¿µ»óÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ  
´ã´çÀÚ : ÁÖÇýÁ¤
¿¬¶ôó : 02-465-9070  
À̸ÞÀÏ : office@intervention.or.kr      
±³À°Á¾·ù : ¿µ»óÀÇÇаúÀÇ»çÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇÇб³À°, ÀÇ·áÁ¤Ã¥
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 7 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í ¿Â¶óÀÎ: »çÀüµî·Ï 10000¿ø / ¿ÀÇÁ¶óÀÎ-»çÀüµî·Ï: Á¤È¸¿ø.ÁØȸ¿ø.±âŸ 50000¿ø, Àü¹®ÀÇ 100000¿ø, °øº¸.Àü°øÀÇ 30000¿ø / ¿ÀÇÁ¶óÀÎ-ÇöÀåµî·Ï: Á¤È¸¿ø.ÁØȸ¿ø.±âŸ 70000¿ø, Àü¹®ÀÇ 120000¿ø, °øº¸.Àü°øÀÇ 50000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 09:00~09:05 IGET Symposium Opening Remark  () 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 09:05~09:20 My strategy of endovascular management for chronic dissection  ¹ÌÁ¤(¹ÌÁ¤) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 09:20~09:35 Long term durability of EVAR : Where do we stand?  °­Ã¤ÈÆ(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 09:35~09:50 Tips and tricks of hostile neck for EVAR  Çöµ¿È£(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 09:50~10:05 Endovascular management of iliac aneurysm  Àü¿ë¼±(ÀÎÇÏÀÇ´ë) 
Åä·Ð 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 10:05~10:20 Discussion  ±èâ¿ø(ºÎ»êÀÇ´ë) 
È޽Ġ07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 10:20~10:30 Coffee break  () 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 10:30~10:45 Recent update of Endovascular treatment of complex aortoiliac disease  À̸í¼ö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 10:45~11:00 Latest results of stents in Femoropopliteal disease  Á¶¼ö¹ü(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 11:00~11:15 Endovascular treatment for femoropopliteal disease by DCB – Korea experience  ±èÁø¿ì(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 11:15~11:30 Latest information of Paclitaxel safety  ½Éµ¿Àç(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 11:30~11:45 What is the best options (POBA, DCB or DES) for BTK interventions?  ¹Ú»ó¿ì(°Ç±¹ÀÇ´ë) 
Åä·Ð 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 11:45~11:55 Discussion  ¿øÁ¦È¯(¾ÆÁÖÀÇ´ë) 
±âŸ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 11:55~12:00 IGET Symposium Closing Remark  () 
½Ä»ç 07-24  12:00~12:55 ½Ä»ç  () 
±âŸ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 12:55~13:00 Á¦29Â÷ Á¤±âÇмú´ëȸ Opening Remark  () 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:00~13:10 The impact of socioeconomic status on mortality in initial TACE candidates for HCC: A Korean national cohort study  ¾ç¿ìÁø(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:10~13:20 Effectiveness of Adding Delayed-phase Cone-beam Computed Tomography for Hepatocellular Carcinomas Dectectability and Treatment  ±è¼­¿µ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:20~13:30 Fluoroscopy-guided Double J urinary stent exchange via transurethral access in Male and Female patients  °ûÁ¤¿ø(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:30~13:40 Lymphatic Embolization versus Sclerotherapy for Symptomatic Post-operative Pelvic Lymphocele (LESPOL): A Randomized Pilot Study  ÀÌÀÎÁØ(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:40~13:50 Plug assisted retrograde trasvenous lymphatic embolization(PARLE) for thoracic duct embolization in chylothorax patient  ±ÇÈÆ(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:50~14:00 Percutaneous lymphatic intervention for the treatment of postoperative lymphatic ascites related to pelvic surgery: analysis of factors affecting outcome  ÀÌ°æ¹Î(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 14:00~14:15 Procedure-related emergency  ¼Û¿µ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 14:15~14:30 Periprocedural Management of Coagulation Status & Hemostasis Risk in Interventional Procedures  ÀÌÀÎÁØ(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 14:30~14:45 Pain control / sedation  ±è¸¸µæ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 14:45~15:00 Surgical perspective  ³ë½Â¿¬(°æÈñÀÇ´ë) 
Åä·Ð 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 15:00~15:10 Discussion  Àü¿õ¹è ±èÇü¿í(ºÎ»êÀÇ´ë Àü³²ÀÇ´ë) 
È޽Ġ07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 15:10~15:30 Coffee break  () 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 15:30~16:00 Diagnostic reference level in IR  À̸í¼ö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:00~16:10 Plug-assisted retrograde transvenous obliteration (PARTO) for duodenal varix via the right gonadal vein  ¾ç¿ìÁø(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:10~16:20 Importance of pedal muscular branch in transcollateral pedal angioplasty  ±èÁ¤Àº(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:20~16:30 Amazing response of advanced HCC with intra-arterial chemotherapy  ±è¼ºÈ£(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:30~16:40 Transcatheter arterial embolization for chronic non-specific back pain (lumbar pain)  ÀÌ»óȯ(¾çÁöº´¿ø) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:40~16:50 lymphovenous microsurgery for intractable chylous ascites : role of intraoperative lymphangiography  Á¤À±¼ö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:50~17:00 Percutaneous sclerotherapy for large thoracoabdominal lymphatic cyst  ½ÅÁöÈÆ(¿ï»êÀÇ´ë) 
Åä·Ð 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 17:00~17:10 Discussion  ÀÌ¿õÈñ °­¿õ·¡(¼øõÇâÀÇ´ë ´ë±¸°¡Å縯´ëÇб³º´¿ø) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 17:10~17:20 Cook Medical  ÀÌ¿ì¶÷(Cook Medical) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 17:20~17:30 ¢ß¼¼¸íMD  ÃÖÁø´ö(¢ß¼¼¸íMD) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 17:30~17:40 Boston Scientific  ÀÌÀºÁÖ(Boston Scientific) 
±³À°½Ã°£ 07-24 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 17:40~17:50 Philips  ±è½ÅÈ£(Philips) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2020³âµµ ´ëÇÑÀ̽ÄÇÐȸ Á¦16Â÷ Ãá°èÇмú´ëȸ (¿Â¶óÀÎ) : 2020-07-24
´ÙÀ½±Û ´ëÇѼºÇü¿Ü°úÇÐȸ Á¦10ȸ ±âÃÊÀç°Ç¼ºÇü Çмú´ëȸ (¿Â¶óÀÎ) : 2020-07-24
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20705 ÀüºÏ ÀüÁÖ½ÃÀÇ»çȸ Ãá°è Çмú´ëȸ(´ç´¢º´, Ç×Ç÷¼ÒÆÇÁ¦, Ç㸮ÅëÁõ, ºñŸ¹ÎD¿Í Ä®½·) : 2024-05-30 0 1 2024-05-25
20704 ºÎ»ê »ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ KSBMB International Conference 2024(1ÀÏÂ÷) : 2024-05-29 0 1 2024-05-25
20703 ¼­¿ï °­¼­±¸ÀÇ»çȸ ¿¬¼ö±³À°(õ½ÄÄ¡·á, °ñ´Ù°øÁõ, ÀÇ·áÇö½Ç) : 2024-05-29 0 3 2024-05-25
20702 ´ë±¸ Çѱ¹¿©ÀÚÀÇ»çȸ ´ë±¸°æºÏÁöȸ 5¿ù Çмú½ÉÆ÷Áö¾ö : 2024-05-28 0 1 2024-05-25
20701 ¼­¿ï Áß±¸ÀÇ»çȸ 2024³â Á¦1Â÷ ȸ¿ø ¿¬¼ö±³À°(°ñ´Ù°ñÁõ ÃÖ½ÅÄ¡·á, Æó·Å±¸±Õ ¹é½Å) : 2024-05-28 0 5 2024-05-25
20700 ºÎ»ê Çѱ¹¿©ÀÚÀÇ»çȸ ºÎ»êÁöȸ 5¿ù Çмú½ÉÆ÷Áö¾ö : 2024-05-28 0 0 2024-05-25
20699 ´ëÀü Á¦ 4ȸ ´ëÇÑ»êºÎÀΰúÃÊÀ½ÆÄÇÐȸ ÃæûÁöȸ ¿¬¼ö°­Á : 2024-05-26 0 6 2024-05-25
20698 ¼­¿ï 2024³â ´ëÇѳëÀκ´ÇÐȸ Á¦73Â÷ Çмú´ëȸ(Ãá°è)(2ÀÏÂ÷) : 2024-05-26 0 1 2024-05-25
20697 ¼­¿ï (¿Â¶óÀÎ) 2024³â ±âº» ¼Ò¾Æ ÀÀ±Þ óġ ±³À°°úÁ¤ 1Â÷(BPECC) : 2024-05-26 0 1 2024-05-25
20696 Ãæ³² Á¦ 28ȸ ¼øõÇâ ºñ´¢ÀÇÇаú ½ÉÆ÷Áö¿ò(2ÀÏÂ÷) : 2024-05-26 0 1 2024-05-25
20695 Ãæ³² Á¦16Â÷ Ä¡¸ÅÁø·áÀÇ»ç Àü¹®È­ ±³À° (»ó¹Ý±â_1ÀÏÂ÷) : 2024-05-26 0 1 2024-05-25
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 95 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 53 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 61 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 70 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷